棕榈酸帕利哌酮治疗非急性期精神分裂症临床观察

Clinical observation of paliperidone palmitate in the treatment of non-acute schizophrenia

目的探讨肌内注射棕榈酸帕利哌酮注射液治疗非急性期精神分裂症患者的临床疗效和安全性。方法对30例非急性期精神分裂症患者予以棕榈酸帕利哌酮肌内注射，观察20周。于治疗前后采用阳性与阴性症状量表、社会功能缺陷筛选量表评定临床疗效，并统计不良反应发生状况。结果治疗4周末起入组患者阳性与阴性症状量表及社会功能缺陷筛选量表评分均较治疗前显著降低（P〈0．01）。治疗过程中出现的不良反应程度轻微，患者可耐受。结论棕榈酸帕利哌酮能显著改善非急性期精神分裂症患者的精神症状和社会功能，安全性高，有利于提高治疗依从性。

Objective To explore the efficacy and safety of paliperidone palmitate intramuscular injection in non-acute schizophrenia patients. Methods Thirty non-acute schizophrenics were treated with paliperidone palmitate injection for 20 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and Social Disability Screening Schedule （SDSS） before and after treatment. Results Since the end of the 4~h week the PANSS and SDSS of the patients lowered more significantly compared with pretreatment （P〈0.01）. Adverse reactions were mild and tolerable. Conclusion Paliperidone palmitate could notably improve psychiatric symptoms and social functions of non-acute schizophrenics, has higher safety, and is beneficial to the improvement of compliance.